,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-01-06 06:30:00,"Chicago, IL - January 06, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.017654621973633766,0.008685778826475143,0.9736595749855042,neutral,0.008968843147158623
1,2017-01-06 06:30:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2017-01-06 06:30:00,"Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ - Free Report ), Barclays (NYSE: BCS - Free Report ), Procter & Gamble (NYSE: PG - Free Report ), Kellogg (NYSE: K - Free Report ) and Medtronic (NYSE: MDT - Free Report ).",0.020491894334554672,0.010721222497522831,0.9687868356704712,neutral,0.009770671837031841
3,2017-01-06 06:30:00,"Today, Zacks is promoting its ''Buy'' stock recommendations.",0.3684377670288086,0.010614300146698952,0.6209479570388794,neutral,0.3578234612941742
4,2017-01-06 06:30:00,Get #1Stock of the Day pick for free.,0.0864095613360405,0.03249066323041916,0.8810997605323792,neutral,0.05391889810562134
5,2017-01-06 06:30:00,"Here are highlights from Thursday's Analyst Blog:

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (NYSE: JNJ - Free Report ), Barclays (NYSE: BCS - Free Report ), and Procter & Gamble (NYSE: PG - Free Report ).",0.02014746703207493,0.01407315582036972,0.9657793641090393,neutral,0.006074311211705208
6,2017-01-06 06:30:00,"Johnson & Johnson shares were up +14.6% last year, widely outperforming the large-cap pharma space (down -3.8%) as well as the S&P 500 index (up +12.1%).",0.9401546716690063,0.03743277117609978,0.022412529215216637,positive,0.9027218818664551
7,2017-01-06 06:30:00,"While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward.",0.894381582736969,0.017315350472927094,0.08830300718545914,positive,0.8770662546157837
8,2017-01-06 06:30:00,We saw this in the company's Q3 earnings report when it beat on the top- and bottom-lines and provided favorable outlook.,0.8165184259414673,0.01803477667272091,0.16544681787490845,positive,0.798483669757843
9,2017-01-06 06:30:00,The analyst expects these trends to continue in the coming periods as well; JNJ is scheduled to report 2016 Q4 results on January 24th.,0.5039097666740417,0.013153783045709133,0.48293644189834595,positive,0.49075597524642944
10,2017-01-06 06:30:00,"(You can read the full research report on Johnson & Johnson here >> )

Barclays shares have struggled for a while, but the British banking giant appears to have a turned the corner lately, with the stock outperforming the Zacks Foreign Banks industry over the past three months.",0.03803034871816635,0.9470604658126831,0.014909130521118641,negative,-0.9090301394462585
11,2017-01-06 06:30:00,"The analyst thinks that this Zacks Rank #1 (Strong Buy) bank is on track to achieve targeted cost savings this year, driven by continued divestiture of non-core operations world-wide.",0.954097330570221,0.016956601291894913,0.02894604206085205,positive,0.937140703201294
12,2017-01-06 06:30:00,"These are expected to improve operational efficiency and lower expenses, thereby leading to improved profitability over time.",0.9497809410095215,0.01753249205648899,0.03268652781844139,positive,0.9322484731674194
13,2017-01-06 06:30:00,"Further, Moody's long term ratings upgrade enhances investors' confidence in the stock.",0.9459653496742249,0.016576869413256645,0.037457726895809174,positive,0.9293884634971619
14,2017-01-06 06:30:00,"(You can read the full research report on Barclays here >> )

Procter & Gamble shares were up +8.5% last year, outperforming the Zacks Consumer Staples sector (+4.1%).",0.9528395533561707,0.028249591588974,0.018910842016339302,positive,0.924589991569519
15,2017-01-06 06:30:00,"The analyst likes the company's strong organic sales, which grew 3% in Q3, the best performance in over two years.",0.957275927066803,0.01965392380952835,0.02307017147541046,positive,0.9376220107078552
16,2017-01-06 06:30:00,Productivity improvements and aggressive cost-saving efforts have consistently improved margins with the trend expected to continue going forward.,0.955879271030426,0.020290249958634377,0.0238304752856493,positive,0.9355890154838562
17,2017-01-06 06:30:00,"On the flip side, the Zacks analyst points to mature end markets and the negative impact of the strong U.S. dollar as some of the headwinds for the stock.",0.0938594713807106,0.6864146590232849,0.21972578763961792,negative,-0.5925551652908325
18,2017-01-06 06:30:00,"The company is expected to report Q4 results on January 24th, with the current Zacks Consensus EPS of $1.07 on $16.8 billion in revenues.",0.27779698371887207,0.011213840916752815,0.7109891772270203,neutral,0.2665831446647644
19,2017-01-06 06:30:00,"(You can read the full research report on Procter & Gamble here >> )

Other noteworthy reports we are featuring today include Kellogg (NYSE: K - Free Report ) and Medtronic (NYSE: MDT - Free Report ).",0.029301324859261513,0.006671111565083265,0.9640275239944458,neutral,0.02263021282851696
20,2017-01-06 06:30:00,"Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks.",0.040785253047943115,0.008477886207401752,0.9507368803024292,neutral,0.03230736777186394
21,2017-01-06 06:30:00,"Valued at $25 each, they are yours to consult over the next 30 days absolutely free.",0.03975151479244232,0.0066274418495595455,0.9536210894584656,neutral,0.03312407433986664
22,2017-01-06 06:30:00,They feature sensitive Zacks Rank information on each stock that you won't find anywhere else.,0.027265066280961037,0.022345593199133873,0.9503893852233887,neutral,0.004919473081827164
23,2017-01-06 06:30:00,"See the reports free >>

Today, Zacks is promoting its ''Buy'' stock recommendations.",0.43709632754325867,0.012021603994071484,0.55088210105896,neutral,0.4250747263431549
24,2017-01-06 06:30:00,Get #1 Stock of the Day pick for free .,0.2226315140724182,0.024793583899736404,0.7525749206542969,neutral,0.1978379338979721
25,2017-01-06 06:30:00,Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.,0.06386703997850418,0.004654404241591692,0.9314785599708557,neutral,0.059212636202573776
26,2017-01-06 06:30:00,"Continuous coverage is provided for a universe of 1,150 publicly traded stocks.",0.036364275962114334,0.004866600502282381,0.9587691426277161,neutral,0.03149767592549324
27,2017-01-06 06:30:00,Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance.,0.054108913987874985,0.005191051866859198,0.9407000541687012,neutral,0.04891786351799965
28,2017-01-06 06:30:00,Recommendations and target prices are six-month time horizons.,0.013092893175780773,0.007127966266125441,0.9797791242599487,neutral,0.0059649269096553326
29,2017-01-06 06:30:00,"Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar.",0.044983625411987305,0.5624399185180664,0.3925764560699463,negative,-0.5174562931060791
30,2017-01-06 06:30:00,They're virtually unknown to the general public.,0.035764459520578384,0.0785161554813385,0.885719358921051,neutral,-0.04275169596076012
31,2017-01-06 06:30:00,"Yet today's 220 Zacks Rank #1 ""Strong Buys"" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015.",0.6580293774604797,0.017276067286729813,0.32469451427459717,positive,0.6407533288002014
32,2017-01-06 06:30:00,Its average gain has been a stellar +26% per year.,0.8422174453735352,0.0191669799387455,0.13861553370952606,positive,0.8230504393577576
33,2017-01-06 06:30:00,See these high-potential stocks free >>.,0.12527841329574585,0.05778927728533745,0.8169323205947876,neutral,0.0674891322851181
34,2017-01-06 06:30:00,"Get the full Report on JNJ - FREE

Get the full Report on BCS - FREE

Get the full Report on PG - FREE

Get the full Report on K - FREE

Get the full Report on MDT - FREE

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.01384279876947403,0.009794828481972218,0.976362407207489,neutral,0.004047970287501812
35,2017-01-06 06:30:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
36,2017-01-06 06:30:00,Inherent in any investment is the potential for loss.,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
37,2017-01-06 06:30:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
38,2017-01-06 06:30:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
39,2017-01-06 06:30:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
40,2017-01-06 06:30:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
41,2017-01-06 06:30:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
42,2017-01-06 06:30:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
43,2017-01-06 06:30:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
44,2017-01-06 06:30:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
45,2017-01-06 06:30:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
46,2017-01-06 06:30:00,Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01078665629029274,0.015373211354017258,0.9738401174545288,neutral,-0.004586555063724518
47,2017-01-06 06:30:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
48,2017-01-06 06:30:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
49,2017-01-06 06:30:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
50,2017-01-06 06:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
